Lumen Technologies hires Sean Alexander as head of Connected Ecosystems
CAMBRIDGE, MA — Tracey L. McCain, Executive Vice President and Chief Legal Officer of Blueprint Medicines Corp (NASDAQ:BPMC), recently disclosed a sale of company stock. According to a Form 4 filing with the Securities and Exchange Commission, McCain sold 5,262 shares of common stock on March 5, 2025, at a price of $88.80 per share, totaling approximately $467,265. The transaction comes as the stock has experienced an 8.3% decline over the past week, according to InvestingPro data.
The sale was made to cover tax withholding obligations associated with the vesting of restricted stock units. This transaction was not a discretionary trade by McCain but was executed automatically to meet these obligations. Following the sale, McCain retains ownership of 66,583 shares of Blueprint Medicines. For comprehensive insider trading analysis and additional insights, InvestingPro subscribers can access detailed reports and real-time alerts.
Blueprint Medicines, headquartered in Cambridge, Massachusetts, is known for its work in developing targeted therapies for genomically defined cancers and rare diseases. The company, currently valued at $5.6 billion, has demonstrated impressive revenue growth of 104% over the last twelve months, with a strong gross profit margin of 96%. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with 8 additional ProTips available to subscribers.
In other recent news, Blueprint Medicines released its fourth-quarter financials for 2024, aligning with consensus expectations and providing revenue guidance for Ayvakit in 2025, estimated between $680 million and $710 million. JMP Securities maintained a Market Outperform rating with a price target of $125, reflecting confidence in the company’s growth trajectory. Stifel analysts also reiterated their Buy rating with a $155 price target, addressing concerns about Ayvakit’s safety, which they found unfounded based on clinical data and discussions with medical professionals.
Citizens JMP expressed optimism about Blueprint Medicines’ prospects, maintaining a $125 price target and highlighting potential sales of Ayvakit reaching $700 million by 2025. The firm emphasized the importance of three-year data demonstrating the drug’s efficacy and safety. Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating and a $150 price target, underscoring the potential of the company’s systemic mastocytosis franchise and the promising outlook for drugs like elenestinib and BLU-808.
Blueprint Medicines’ financial standing remains strong, bolstered by an $80 million inflow from a recent acquisition, bringing its cash reserves to $909.3 million. The company’s focus on precision therapies and the development of Ayvakit continue to be central to its strategy, with ongoing trials expected to further solidify its market position. Recent analyst ratings and targets reflect a positive sentiment towards the company’s future performance, despite recent market volatility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.